Potential

Our aim is to develop a proprietary magnetic nanoparticle technology, the HemoSystem, to allow more selective, efficient, and milder removal of disease-related compounds in patients’ blood. 

Project Description

hemotune AG is developing a proprietary magnetic nanoparticle technology, the HemoSystem, to allow more selective, efficient, and milder removal of disease-related compounds in patients’ blood.

Sepsis is the most severe form of an infection in which the body's own defense reaction damages the body’s tissue and organs, leading to a life-threatening situation. The World Health Organization estimates that around 50 million people worldwide are affected by sepsis every year, causing 11 million deaths, or 20% of all global deaths.

The HemoSystem consists of three components: the HemoDevice, a dialysis-machine-like device that performs the treatment; the HemoDisposable, a disposable set containing all tubing and plastic parts that come into direct contact with the blood; and the HemoSorbent, a mixture of magnetic beads – so-called HemoBeads – that are directed against multiple disease-related compounds.

While traditional blood-purification devices use non-specific dialysis filters or adsorber cartridges, the HemoSystem is based on a mixture of nanostructured magnetic beads that contain a magnetic core and specific binding agents that allow them to interact only with selected targets. During treatment, a magnetic filter efficiently removes beads and bound targets before the blood is returned to the patient. This direct application of a mixture of different beads is unique in that it allows for the simultaneous removal of multiple disease-related compounds, which would not be achievable using drugs.

During the tenure at Wyss Zurich, the team advanced the technology and defined the regulatory strategy for magnetic blood purification as a medical device. 

Contact

hemotune AG
info@hemotune.ch

Faculty Mentor

Wendelin Stark

Portrait stark 560

Partners and Funding

Project Partners

  • ETH Zurich, Functional Materials Laboratory

Funding Partners

  • EU Horizon 2020
  • Eurostars/Eureka
  • Gebert Rüf Foundation
  • Multiple Innosuisse Projects
  • Venture Kick

Achievements

03/2024
Closing Series B2 funding with CHF 14.2M

hemotune AG announced the successful closing of a CHF 14M Series B2 round. Read more.

08/2023
Achieved ISO 13485 certification for QMS

12/2022
Wyss Zurich project completion

hemotune AG exits Wyss Zurich and is now part of our alumni group.

11/2022
hemotune AG awarded by Frost & Sullivan

hemotune AG wins Frost & Sullivan’s 2022 Europe Technology Innovation Leadership Award in the blood purification technology market.

10/2022
Winner of Red Dot Design Award 2022

hemotune AG wins the Red Dot Award: Design Concept 2022 in Singapore. 

06/2022
Finalist at Swiss Economic Award 2022

hemotune AG is a finalist for the Swiss Economic Award 2022. See the live pitch here.

05/2022
Winner of German Innovation Award 2022

hemotune AG wins the German Innovation Award 2022 in the category Medical Technologies. Read more.

04/2022
Closing Series B1 funding with CHF 7.25M

hemotune AG has raised CHF 7.25M in Series B1 funding with an investment consortium. Read more.

03/2022
Innosuisse Scale-up Award 2022

hemotune AG has qualified for the 2nd phase of the Innosuisse Scale-up Programme and receives the Innosuisse Scale-up Programme Award. Read more.

06/2021
Selected for the Venture Leaders MedTech 2021

hemotune AG is one of the ten startups that is part of the first Venture Leaders Medtech program. Read more.

02/2021
hemotune AG on the Cover of Forbes DACH

hemotune AG is Top 1 Spin-Off to watch and makes it on the Cover of Forbes DACH. Read the article.

11/2020
Winner of Swiss Technology Award 2020

hemotune AG wins the Swiss Technology Award 2020 in the "Start up" category.

08/2020
Closing of Series A funding with CHF 5.1M

hemotune AG has closed a CHF 5.1 million Series A funding round with an investment consortium.

07/2020
Supported by the EIT Health

hemotune AG among 11 startups supported by the EIT health Start-up Rescue Instrument.

02/2020
hemotune AG receives grant from Innosuisse

hemotune AG receives an Innosuisse grant worth CHF 580’000.

06/2018
Finalist at W.A. De Vigier Award 2018

hemotune AG is among the 10 finalists of the prestigious De Vigier Award. 

09/2017
hemotune AG incorporation

The ETH Zurich spin-off hemotune is incorporated as hemotune AG.

07/2017
Venture Kick Stage III support

hemotune AG wins Venture Kick Stage III support.

05/2017
Wyss Zurich admission

hemotune is accepted as a full project.

Founding Team

Lukas langenegger portrait

Lukas Langenegger

Co-Founder

Carlos mora portrait

Carlos Mora

Co-Founder

Do you have a breakthrough project you want us to know about?

We invite you to contact the Wyss Zurich office to discuss your project and start the evaluation process.